SCHEMBL5360955

SCHEMBL5360955

O=C1c2cccc(N3CCNCC3)c2Oc2ccc(F)cc2N1Cc1ccc(F)cc1

nearest known ligand 0.80

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.80
LMNA P02545 2/20 0.49
EGFR P00533 4/20 0.48
UBE2N P61088 2/20 0.47
HPGD P15428 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ADRA1D P25100 3/20 0.43
ADRA1A P35348 3/20 0.43
ADRA1B P35368 3/20 0.43
HTR7 P34969 1/20 0.42
TDP1 Q9NUW8 1/20 0.40
CASP3 P42574 1/20 0.40
ALDH3A1 P30838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364715 0.95 HTR6 (0.82) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5361156 0.92 HTR6 (0.68) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5364738 0.92 HTR6 (0.79) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5368470 0.90 HTR6 (0.79) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5362910 0.89 HTR6 (1.00) HTR6LMNAEGFRUBE2NTDP1
SCHEMBL5356843 0.87 HTR6 (0.70) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5366505 0.86 HTR6 (0.74) HTR6LMNAEGFRUBE2NTDP1
SCHEMBL5361668 0.84 HTR6 (0.66) HTR6LMNAEGFRADRA1DADRA1A
SCHEMBL5364868 0.84 HTR6 (0.69) HTR6LMNAEGFRUBE2NHPGD
SCHEMBL5372213 0.83 HTR6 (0.68) HTR6LMNAHPGDADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US claimed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US claimed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO claimed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 HTR6 1/4885LMNA 1520/4885EGFR 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.